ATC Group: C08CA04 Nicardipine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C08CA04 in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C08 Calcium channel blockers
3 C08C Selective calcium channel blockers with mainly vascular effects
4 C08CA Dihydropyridine derivatives
5 C08CA04 Nicardipine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 90 mg
PAREN - Parenteral 90 mg

Active ingredients in C08CA04

Active Ingredient Description
Nicardipine

Nicardipine is a second generation slow calcium channel inhibitor, and belongs to the phenyl-dihydropyridine group. Nicardipine has a greater selectivity for L-type calcium channels in vascular smooth muscle than cardiac myocytes. Nicardipine produces smooth muscle relaxation and marked peripheral vasodilatation.

Related product monographs

Title Information Source Document Type  
CARDENE Hard capsule Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
CARDENE IV Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicines in this ATC group

United States (US)

France (FR)

Japan (JP)

Netherlands (NL)

Singapore (SG)

Tunisia (TN)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.